GLSI
Greenwich LifeSciences, Inc.$14.08+1.28 (+10.00%)Prev Close$12.80·MCap$287.3M·P/E—·Vol83.4K·Yield—
▲
Buys (12M)
11
$586.3K
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$586.3K
●
Active Insiders
1
last 12 mo
Over the past 12 months, insider activity at Greenwich LifeSciences, Inc. (GLSI) has been exclusively buying, with 11 insider purchases totaling $586.3K and 0 insider sales totaling $0.00. The most recent insider transaction was by Patel Snehal (director, 10 percent owner, officer: CEO and CFO), who purchased $29.6K worth of shares on Jul 30, 2026. Greenwich LifeSciences, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $287.3M.
GLSI Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | Buy | 2,200 | $13.43 | $29.6K | 5,611,402 |
| Jul 29, 2026 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | Buy | 1,500 | $13.62 | $20.4K | 5,609,202 |
| Jul 27, 2026 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | Buy | 3,600 | $13.06 | $47.0K | 5,607,702 |
| Jan 13, 2026 | Patel Snehal | CEO and CFO | Buy | 1,800 | $29.83 | $53.7K | 0 |
| Jan 12, 2026 | Patel Snehal | CEO and CFO | Buy | 2,900 | $27.54 | $79.9K | 0 |
| Dec 31, 2025 | Patel Snehal | CEO and CFO | Buy | 4,300 | $21.36 | $91.8K | 0 |
| Dec 30, 2025 | Patel Snehal | CEO and CFO | Buy | 2,900 | $21.73 | $63.0K | 0 |
| Dec 18, 2025 | Patel Snehal | CEO and CFO | Buy | 4,100 | $12.62 | $51.7K | 0 |
| Nov 25, 2025 | Patel Snehal | CEO and CFO | Buy | 4,600 | $8.37 | $38.5K | 0 |
| Nov 7, 2025 | Patel Snehal | CEO and CFO | Buy | 10,600 | $8.43 | $89.4K | 0 |
| Oct 31, 2025 | Patel Snehal | CEO and CFO | Buy | 2,300 | $9.26 | $21.3K | 0 |
| Apr 25, 2025 | Patel Snehal | CEO and CFO | Buy | 3,600 | $9.88 | $35.6K | 0 |
| Apr 17, 2025 | Patel Snehal | CEO and CFO | Buy | 5,400 | $8.98 | $48.5K | 0 |
| Apr 7, 2025 | Patel Snehal | CEO and CFO | Buy | 3,600 | $9.10 | $32.8K | 0 |
| Apr 4, 2025 | Patel Snehal | CEO and CFO | Buy | 5,500 | $8.73 | $48.0K | 0 |
| Jan 13, 2025 | Patel Snehal | CEO and CFO | Buy | 2,500 | $12.51 | $31.3K | 5,552,502 |
| Jan 8, 2025 | Patel Snehal | CEO and CFO | Buy | 2,900 | $13.58 | $39.4K | 5,550,002 |
| Jan 7, 2025 | Patel Snehal | CEO and CFO | Buy | 3,400 | $12.95 | $44.0K | 5,547,102 |
| Jan 6, 2025 | Patel Snehal | CEO and CFO | Buy | 2,000 | $11.97 | $23.9K | 5,543,702 |
| Jan 3, 2025 | Patel Snehal | CEO and CFO | Buy | 2,400 | $11.36 | $27.3K | 5,541,702 |
| Jan 2, 2025 | Patel Snehal | CEO and CFO | Buy | 3,200 | $11.12 | $35.6K | 5,539,302 |
| Nov 25, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 1,000 | $12.91 | $12.9K | 264,148 |
| Sep 30, 2024 | Patel Snehal | CEO and CFO | Buy | 1,500 | $14.63 | $21.9K | 5,536,102 |
| Sep 16, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 800 | $13.85 | $11.1K | 263,148 |
| Aug 8, 2024 | Patel Snehal | CEO and CFO | Buy | 2,000 | $13.81 | $27.6K | 5,534,602 |
| Aug 7, 2024 | Patel Snehal | CEO and CFO | Buy | 5,500 | $13.18 | $72.5K | 5,532,602 |
| Aug 5, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 1,000 | $15.15 | $15.2K | 262,348 |
| Jul 24, 2024 | Patel Snehal | CEO and CFO | Buy | 1,500 | $15.89 | $23.8K | 5,527,102 |
| Jul 22, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 1,000 | $16.00 | $16.0K | 261,348 |
| Jun 17, 2024 | Patel Snehal | CEO and CFO | Buy | 174,825 | $14.30 | $2.50M1.3% OS | 5,525,602 |
| Apr 3, 2024 | Patel Snehal | CEO and CFO | Buy | 3,000 | $19.08 | $57.2K | 5,350,777 |
| Mar 26, 2024 | Patel Snehal | CEO and CFO | Buy | 2,500 | $19.98 | $50.0K | 5,347,777 |
| Mar 22, 2024 | Patel Snehal | CEO and CFO | Buy | 1,500 | $17.68 | $26.5K | 5,345,277 |
| Mar 7, 2024 | Patel Snehal | CEO and CFO | Buy | 30,500 | $12.49 | $380.9K | 5,343,777 |
| Mar 6, 2024 | Patel Snehal | CEO and CFO | Buy | 4,100 | $13.03 | $53.4K | 5,340,277 |
| Feb 21, 2024 | Patel Snehal | CEO and CFO | Buy | 10,800 | $11.16 | $120.5K | 5,336,177 |
| Feb 20, 2024 | Patel Snehal | CEO and CFO | Buy | 12,700 | $11.07 | $140.6K | 5,325,377 |
| Nov 14, 2023 | Patel Snehal | CEO and CFO | Buy | 5,000 | $10.17 | $50.8K | 5,312,677 |
| Nov 7, 2023 | Patel Snehal | CEO and CFO | Buy | 3,500 | $9.11 | $31.9K | 5,307,677 |
| Oct 31, 2023 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 500 | $8.57 | $4.3K | 260,348 |
| Oct 30, 2023 | Patel Snehal | CEO and CFO | Buy | 2,500 | $7.97 | $19.9K | 5,304,177 |
| Oct 27, 2023 | Patel Snehal | CEO and CFO | Buy | 2,500 | $7.91 | $19.8K | 5,301,677 |
| Oct 12, 2023 | Patel Snehal | CEO and CFO | Buy | 1,000 | $9.07 | $9.1K | 5,299,177 |
| Oct 5, 2023 | Patel Snehal | CEO and CFO | Buy | 2,000 | $8.63 | $17.3K | 5,298,177 |
| Sep 28, 2023 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 600 | $8.71 | $5.2K | 259,848 |
| Sep 21, 2023 | Patel Snehal | CEO and CFO | Buy | 4,000 | $8.95 | $35.8K | 5,296,177 |
| Sep 13, 2023 | Patel Snehal | CEO and CFO | Buy | 1,000 | $9.48 | $9.5K | 5,292,177 |
| Aug 24, 2023 | Patel Snehal | CEO and CFO | Buy | 1,000 | $9.97 | $10.0K | 5,291,177 |
| Aug 8, 2023 | Patel Snehal | CEO and CFO | Buy | 2,000 | $10.55 | $21.1K | 5,290,177 |
| Jul 25, 2023 | Patel Snehal | CEO and CFO | Buy | 1,000 | $9.20 | $9.2K | 5,288,177 |
Showing 1–50 of 105
1 / 3
GLSI Insider Buying Activity
The following table shows recent insider purchases of Greenwich LifeSciences, Inc. (GLSI) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | Buy | 2,200 | $13.43 | $29.6K | 5,611,402 |
| Jul 29, 2026 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | Buy | 1,500 | $13.62 | $20.4K | 5,609,202 |
| Jul 27, 2026 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | Buy | 3,600 | $13.06 | $47.0K | 5,607,702 |
| Jan 13, 2026 | Patel Snehal | CEO and CFO | Buy | 1,800 | $29.83 | $53.7K | 0 |
| Jan 12, 2026 | Patel Snehal | CEO and CFO | Buy | 2,900 | $27.54 | $79.9K | 0 |
| Dec 31, 2025 | Patel Snehal | CEO and CFO | Buy | 4,300 | $21.36 | $91.8K | 0 |
| Dec 30, 2025 | Patel Snehal | CEO and CFO | Buy | 2,900 | $21.73 | $63.0K | 0 |
| Dec 18, 2025 | Patel Snehal | CEO and CFO | Buy | 4,100 | $12.62 | $51.7K | 0 |
| Nov 25, 2025 | Patel Snehal | CEO and CFO | Buy | 4,600 | $8.37 | $38.5K | 0 |
| Nov 7, 2025 | Patel Snehal | CEO and CFO | Buy | 10,600 | $8.43 | $89.4K | 0 |
| Oct 31, 2025 | Patel Snehal | CEO and CFO | Buy | 2,300 | $9.26 | $21.3K | 0 |
| Apr 25, 2025 | Patel Snehal | CEO and CFO | Buy | 3,600 | $9.88 | $35.6K | 0 |
| Apr 17, 2025 | Patel Snehal | CEO and CFO | Buy | 5,400 | $8.98 | $48.5K | 0 |
| Apr 7, 2025 | Patel Snehal | CEO and CFO | Buy | 3,600 | $9.10 | $32.8K | 0 |
| Apr 4, 2025 | Patel Snehal | CEO and CFO | Buy | 5,500 | $8.73 | $48.0K | 0 |
| Jan 13, 2025 | Patel Snehal | CEO and CFO | Buy | 2,500 | $12.51 | $31.3K | 5,552,502 |
| Jan 8, 2025 | Patel Snehal | CEO and CFO | Buy | 2,900 | $13.58 | $39.4K | 5,550,002 |
| Jan 7, 2025 | Patel Snehal | CEO and CFO | Buy | 3,400 | $12.95 | $44.0K | 5,547,102 |
| Jan 6, 2025 | Patel Snehal | CEO and CFO | Buy | 2,000 | $11.97 | $23.9K | 5,543,702 |
| Jan 3, 2025 | Patel Snehal | CEO and CFO | Buy | 2,400 | $11.36 | $27.3K | 5,541,702 |
| Jan 2, 2025 | Patel Snehal | CEO and CFO | Buy | 3,200 | $11.12 | $35.6K | 5,539,302 |
| Nov 25, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 1,000 | $12.91 | $12.9K | 264,148 |
| Sep 30, 2024 | Patel Snehal | CEO and CFO | Buy | 1,500 | $14.63 | $21.9K | 5,536,102 |
| Sep 16, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 800 | $13.85 | $11.1K | 263,148 |
| Aug 8, 2024 | Patel Snehal | CEO and CFO | Buy | 2,000 | $13.81 | $27.6K | 5,534,602 |
| Aug 7, 2024 | Patel Snehal | CEO and CFO | Buy | 5,500 | $13.18 | $72.5K | 5,532,602 |
| Aug 5, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 1,000 | $15.15 | $15.2K | 262,348 |
| Jul 24, 2024 | Patel Snehal | CEO and CFO | Buy | 1,500 | $15.89 | $23.8K | 5,527,102 |
| Jul 22, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 1,000 | $16.00 | $16.0K | 261,348 |
| Jun 17, 2024 | Patel Snehal | CEO and CFO | Buy | 174,825 | $14.30 | $2.50M1.3% OS | 5,525,602 |
| Apr 3, 2024 | Patel Snehal | CEO and CFO | Buy | 3,000 | $19.08 | $57.2K | 5,350,777 |
| Mar 26, 2024 | Patel Snehal | CEO and CFO | Buy | 2,500 | $19.98 | $50.0K | 5,347,777 |
| Mar 22, 2024 | Patel Snehal | CEO and CFO | Buy | 1,500 | $17.68 | $26.5K | 5,345,277 |
| Mar 7, 2024 | Patel Snehal | CEO and CFO | Buy | 30,500 | $12.49 | $380.9K | 5,343,777 |
| Mar 6, 2024 | Patel Snehal | CEO and CFO | Buy | 4,100 | $13.03 | $53.4K | 5,340,277 |
| Feb 21, 2024 | Patel Snehal | CEO and CFO | Buy | 10,800 | $11.16 | $120.5K | 5,336,177 |
| Feb 20, 2024 | Patel Snehal | CEO and CFO | Buy | 12,700 | $11.07 | $140.6K | 5,325,377 |
| Nov 14, 2023 | Patel Snehal | CEO and CFO | Buy | 5,000 | $10.17 | $50.8K | 5,312,677 |
| Nov 7, 2023 | Patel Snehal | CEO and CFO | Buy | 3,500 | $9.11 | $31.9K | 5,307,677 |
| Oct 31, 2023 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 500 | $8.57 | $4.3K | 260,348 |
| Oct 30, 2023 | Patel Snehal | CEO and CFO | Buy | 2,500 | $7.97 | $19.9K | 5,304,177 |
| Oct 27, 2023 | Patel Snehal | CEO and CFO | Buy | 2,500 | $7.91 | $19.8K | 5,301,677 |
| Oct 12, 2023 | Patel Snehal | CEO and CFO | Buy | 1,000 | $9.07 | $9.1K | 5,299,177 |
| Oct 5, 2023 | Patel Snehal | CEO and CFO | Buy | 2,000 | $8.63 | $17.3K | 5,298,177 |
| Sep 28, 2023 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 600 | $8.71 | $5.2K | 259,848 |
| Sep 21, 2023 | Patel Snehal | CEO and CFO | Buy | 4,000 | $8.95 | $35.8K | 5,296,177 |
| Sep 13, 2023 | Patel Snehal | CEO and CFO | Buy | 1,000 | $9.48 | $9.5K | 5,292,177 |
| Aug 24, 2023 | Patel Snehal | CEO and CFO | Buy | 1,000 | $9.97 | $10.0K | 5,291,177 |
| Aug 8, 2023 | Patel Snehal | CEO and CFO | Buy | 2,000 | $10.55 | $21.1K | 5,290,177 |
| Jul 25, 2023 | Patel Snehal | CEO and CFO | Buy | 1,000 | $9.20 | $9.2K | 5,288,177 |
GLSI Insider Selling Activity
The following table shows recent insider sales of Greenwich LifeSciences, Inc. (GLSI) stock reported via SEC Form 4 filings.
No insider selling activity found for GLSI in the last 12 months.
GLSI Insiders
Patel Snehal
director, 10 percent owner, officer: CEO and CFO
Bought $6.53M
79 tradesLast: Jul 30, 2026
Similar Stocks to GLSI
VRTX
Vertex Pharmaceuticals Incorporated
$479.25-0.84%
$121.16B
REGN
Regeneron Pharmaceuticals, Inc.
$733.89+5.54%
$67.58B
RVMD
Revolution Medicines, Inc.
$191.43+5.81%
$40.23B
ALNY
Alnylam Pharmaceuticals, Inc.
$198.99-30.54%
$36.28B
INCY
Incyte Corporation
$122.89-3.34%
$23.51B
INSM
Insmed Incorporated
$100.93-2.06%
$23.18B
UTHR
United Therapeutics Corporation
$525.18+0.03%
$22.43B
MRNA
Moderna, Inc.
$57.56+5.74%
$21.45B